|
06 Aug 2022 |
U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
|
|
06 Aug 2022 |
Enhertu approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
|
|
05 Aug 2022 |
Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China
|
|
05 Aug 2022 |
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
|
|
05 Aug 2022 |
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
|
|
05 Aug 2022 |
Gilead Sciences to acquire MiroBio
|
|
05 Aug 2022 |
Amgen to acquire Chemocentryx for $4 billion in cash
|
|
04 Aug 2022 |
Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
|
|
04 Aug 2022 |
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
|
|
04 Aug 2022 |
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
|
|
04 Aug 2022 |
Eisai presents new findings on lecanemab's investigational subcutaneous formulation and modeling simulation of ApoE4 genotype on ARIA-E incidence at the Alzheimer's Association International Conference (AAIC) 2022
|
|
04 Aug 2022 |
Radiopharm enters into strategic collaboration with Lantheus and assumes PD-L1 licensing agreement from Nanomab
|
|
04 Aug 2022 |
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
|
|
04 Aug 2022 |
ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial
|
|
04 Aug 2022 |
OliX Pharmaceuticals Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-related Macular Degeneration
|
|
04 Aug 2022 |
European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
|
|
03 Aug 2022 |
Avenge Bio Announces FDA Clearance of the AVB-001 IND for the Treatment of Ovarian Cancer, a Novel Cellular Therapy Leveraging the LOCOcyte™ Immunotherapy Platform
|
|
03 Aug 2022 |
ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer
|
|
03 Aug 2022 |
Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors
|
|
03 Aug 2022 |
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
|
